Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sorin Group wins approval for Reply pacemakers
The Reply pacemaker which is said to be the world’s smallest dual chamber pacemaker at 8cc’s is Sorin Group’s next pacing evolution designed to reduce ventricular pacing and
The Reply pacemaker which is said to be the world’s smallest dual chamber pacemaker at 8cc’s is Sorin Group’s next pacing evolution designed to reduce ventricular pacing and
Thomas Kindt, chief scientific officer of InNexus, said: “We are beginning a study in cynomolgus monkeys of DXL625, an antibody directed against the B-cell marker CD20 and enhanced
The technology, which will be used by Covidien’s respiratory and monitoring solutions business unit, reflects the company’s strong commitment to making investments in clinically relevant product innovations designed
Under the terms of the agreements, Orthofix will fund a milestone based program to develop a bone growth matrix that will be designed to provide beneficial properties comparable
The committee has informed the company that the cumulative safety data generated thus far from the Emerald and Pearl Phase III trials support continuation of the studies. In
The new trial will employ two immunotherapeutic vaccines designed to work in concert to activate the immune system to recognize and kill tumor cells in breast and ovarian
The study demonstrated that Chrysalin extensively decreases myocardial injury when administered following a major ischemic insult. Endpoints of the study included infarct size, coronary microvessel function, myocardial function
The drug candidate was studied by Odyssey Thera as part of the ongoing collaboration with Pfizer. The achievement of this milestone is said to be the company’s first
Upon completion of the arrangement, Calyx will be the holder of all of the assets, property and undertaking of Chromos, together with additional cash of $2.35 million (before
The FDA has accepted SuperGen’s application upon review of data from in vitro studies in glioblastoma cell lines that demonstrate that either MP-470 or ionizing radiation alone induce